Prices are updated after-hours

Manufacturing Nasdaq

Ondas Holdings Inc

ONDS 4 | $0.8401 -9.67% -10.7% 200K

|

(0.0% 1d) (-13.8% 1m) (-4.4% 1y) (0.0% 2d) (-6.7% 3d) (-11.1% 7d) (82.28% volume)
Earnings Calendar: 2024-04-01
Market Cap: $ 55,110,560
https://www.ondas.com
Sec Filling | Patents | 15 employees

(United States) Ondas Holdings Inc., through its wholly owned subsidiary, Ondas Networks Inc., is a developer of private licensed wireless data networks for mission-critical industrial markets. The Company designs and manufactures its multi-patented, Software Defined Radio (SDR) platform for Mission Critical IoT (MC- IoT) applications. Ondas Networks' customer end markets include utilities, oil and gas, transportation, and government entities whose demands span a wide range of mission critical applications that require secure communications over large and diverse geographical areas, many of which are within challenging radio frequency environments. Customers use the Company's SDR technology to deploy their own private licensed broadband wireless networks. The Company also offers mission-critical entities the option of a managed network service. Ondas Networks' SDR technology supports IEEE 802.16s, the new worldwide standard for private licensed wide area industrial networks.

urea communication security

add to watch list Paper trade email alert is off

Wrap Technologies Inc

WRAP | News | $2.01 -3.37% -3.48% 180K

|

(0.0% 1d) (-24.2% 1m) (49.3% 1y) (0.0% 2d) (4.7% 3d) (4.2% 7d) (-42.32% volume)
Earnings Calendar: 2024-04-30
Market Cap: $ 88,870,480
https://wrap.com
Sec Filling | Patents | 52 employees

Wrap Technologies is an innovator of modern policing solutions. The Company's BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar® tether to restrain an individual at a distance from 10 to 25 feet. Developed by award winning inventor Elwood Norris, the Company's Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement in safely and effectively deescalating encounters, especially those involving an individual in crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury in Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth, and Oak Ridge.

add to watch list Paper trade email alert is off

ComSovereign Holding Corp

COMS | $0.2595 37.35% 720

|

(0.0% 1d) (20.0% 1m) (-87.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-82.04% volume)
Earnings Calendar:
Market Cap: $ 699,414
https://www.comsovereign.com/
Sec Filling | Patents | 112 employees

(US) COMSovereign Holding Corp. (Nasdaq: COMS) has assembled a portfolio of communications technology companies that enhance connectivity across the entire data transmission spectrum. Through strategic acquisitions and organic research and development efforts, COMSovereign has become a U.S.-based communications provider able to provide 4G LTE Advanced and 5G-NR telecom solutions to network operators and enterprises.

acquisitions communication 5g

add to watch list Paper trade email alert is off

Eledon Pharmaceuticals Inc

ELDN | $1.85 -7.03% -7.57% 420K

|

(0.0% 1d) (-1.1% 1m) (-29.8% 1y) (0.0% 2d) (0.0% 3d) (13.4% 7d) (2408.23% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 45,904,291
http://novustherapeutics.com/
Sec Filling | Patents | 10 employees

(US) Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company’s lead compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is widely recognized for its prominent role in immune regulation. CD40L is primarily expressed on activated CD4+ T cells, platelets and endothelial cells while the CD40 receptor is constitutively expressed on antigen presenting cells such as B cells, macrophages, and dendritic cells. By blocking CD40L and not the CD40 receptor, AT-1501 inhibits both the CD40 and CD11 costimulatory signaling pathways, providing the potential for improved efficacy compared to anti-CD40 receptor approaches. Blocking CD40L also increases polarization of CD4+ lymphocytes to Tregs, a specialized subpopulation of T cells that act to suppress an immune response, thus creating a more tolerogenic environment, which is especially important for autoimmune diseases and in the transplant setting. Furthermore AT-1501 is an IgG1 antibody specifically engineered to cripple the Fc effector function to potentially improve safety, as well as potentially provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other approaches.

als ceiling treatment antibody t-cell

add to watch list Paper trade email alert is off

Star Equity Holdings Inc

STRR | $0.889 4.53% 4.33% 9K

|

(0.0% 1d) (-3.4% 1m) (7.5% 1y) (0.0% 2d) (-2.3% 3d) (-2.8% 7d) (89.69% volume)
Earnings Calendar: 2024-03-13
Market Cap: $ 14,089,052
https://www.digirad.com/
Sec Filling | Patents | 636 employees

(US) Star Equity Holdings, Inc. is a diversified holding company committed to growing shareholder value through operational excellence and disciplined capital allocation.

add to watch list Paper trade email alert is off

KemPharm Inc

KMPH | $5.46 6.04% 0

|

(0.0% 1d) (0.7% 1m) (0.0% 1y) (0.0% 2d) (0.0% 3d) (0.7% 7d) (NaN% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 188,396,547
http://www.kempharm.com/
Sec Filling | Patents | 22 employees

(US) KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.

urea treatment profitable

add to watch list Paper trade email alert is off

Qilian International Holding Group ltd

QLI | $0.7382 -4.14% -4.32% 8.8K

|

(0.0% 1d) (27.8% 1m) (-33.9% 1y) (0.0% 2d) (-12.4% 3d) (11.4% 7d) (-92.01% volume)
Earnings Calendar:
Market Cap: $ 26,390,650
https://ir.qlsyy.net
Sec Filling | Patents | 292 employees

Qilian International Holding Group Limited, headquartered in Gansu, China, is a pharmaceutical and chemical products manufacturer in China. It focuses on the development, manufacture, marketing and sale of licorice products, oxytetracycline products, traditional Chinese medicine derivatives product, heparin product, sausage casings, and fertilizers. The Company’s products are sold in more than 20 provinces in China.

fertilizer

add to watch list Paper trade email alert is off

Axon Enterprise Inc

AXON 4 | $293.72 -1.3% -1.32% 540K

|

(0.0% 1d) (-7.1% 1m) (30.5% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (5.13% volume)
Earnings Calendar: 2024-02-27
Market Cap: $ 22,165,087,525
https://www.axon.com/
Sec Filling | Patents | 1710 employees

(US) Axon is a network of devices, apps and people that helps public safety personnel become smarter and safer. With a mission of protecting life, its technologies give customers the confidence, focus and time they need to keep their communities safe. Its products impact every aspect of a public safety officer's day-to-day experience with the goal of helping everyone get home safe.

add to watch list Paper trade email alert is off

Alto Ingredients Inc

ALTO | $1.93 1.05% 1.04% 330K

|

(0.0% 1d) (-0.5% 1m) (50.8% 1y) (0.0% 2d) (0.0% 3d) (-4.9% 7d) (-18.92% volume)
Earnings Calendar: 2024-03-11
Market Cap: $ 146,095,500
http://www.pacificethanol.net/
Sec Filling | Patents | 370 employees

(US) Alto Ingredients, Inc., formerly known as Pacific Ethanol, Inc., is a leading producer of specialty alcohols and essential ingredients. The company is focused on products for four key markets: Health, Home & Beauty; Food & Beverage; Essential Ingredients; and Renewable Fuels. The company's customers include major food and beverage companies and consumer products companies.

renewable

add to watch list Paper trade email alert is off

GT Biopharma Inc

GTBP | $3.8001 1.3% 5.9K

|

(0.0% 1d) (-3.1% 1m) (822.5% 1y) (0.0% 2d) (-7.1% 3d) (-2.9% 7d) (1.62% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 5,246,543
https://www.gtbiopharma.com/
Sec Filling | Patents | 2018 employees

(US) GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology.

ceiling cancer t-cell

add to watch list Paper trade email alert is off

Amplitech Group Inc

AMPG | $2.39 7.66% 7.11% 6.8K

|

(0.0% 1d) (23.0% 1m) (-26.5% 1y) (0.0% 2d) (0.0% 3d) (-1.3% 7d) (-35.37% volume)
Earnings Calendar: 2023-11-13
Market Cap: $ 23,223,900
https://www.amplitechinc.com
Sec Filling | Patents | 16 employees

AmpliTech Group, Inc. designs, develops, and manufactures custom and standard state-of-the-art RF components for the Domestic and International, SATCOM, Space, Defense and Military markets. These designs cover the frequency range from 50 kHz to 40 GHz - eventually, offering designs up to 100 GHz. AmpliTech also provides consulting services to help with any microwave components or systems design problems. Its steady growth over the past 13+ years has come about because AmpliTech can provide complex, custom solutions for nearly ANY custom requirements that are presented. In addition, AmpliTech has the best assemblers, wires, and technicians in the industry and can provide contract assembly of customers' own designs.

military defense

add to watch list Paper trade email alert is off

Quipt Home Medical Corp New

QIPT | $3.86 -2.28% -2.33% 88K

|

(0.0% 1d) (-6.3% 1m) (-30.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-10.39% volume)
Earnings Calendar: 2023-12-18
Market Cap: $ 164,326,079
https://www.protechhomemedical.com
Sec Filling | Patents | n/a employees

The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services and making life easier for the patient.

respiratory education

add to watch list Paper trade email alert is off

Zivo Bioscience Inc

ZIVO 4 | $8.0 -17.81% 270

|

(0.0% 1d) (-9.1% 1m) (-55.1% 1y) (0.0% 2d) (15.9% 3d) (17.5% 7d) (-17.26% volume)
Earnings Calendar:
Market Cap: $ 22,423,904
https://zivobioscience.com/
Sec Filling | Patents | 8 employees

(United States) ZIVO Bioscience, Inc. is a Michigan-based biotech/agtech company dedicated to harnessing the immune health and nutritional benefits of bioactive compounds derived from its proprietary algal cultures. The development pipeline includes natural products for use as dietary supplements and functional food ingredients, as well as innovative, biologically derived and synthesized candidates designed to deliver medicinal and pharmaceutical benefits for humans and animals, with a specific focus on modulating the immune and inflammatory response.

animals

add to watch list Paper trade email alert is off

High Tide Inc.

HITI | $2.255 2.04% 2.0% 730K

|

(0.0% 1d) (33.1% 1m) (80.9% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (NaN% volume)
Earnings Calendar: 2024-01-29
Market Cap: $ 178,901,478
https://hightideinc.com
Sec Filling | Patents | n/a employees

(CA) High Tide is a retail-focused cannabis company enhanced by the manufacturing and distribution of consumption accessories. The Company is the largest Canadian retailer of recreational cannabis as measured by revenue, with 80 branded retail cannabis locations spanning Ontario, Alberta, Manitoba and Saskatchewan. High Tide's retail segment features the Canna Cabana,KushBar, Meta Cannabis Co., Meta Cannabis Supply Co. and NewLeaf Cannabis banners, with additional locations under development across the country. High Tide has been serving consumers for over a decade through its numerous consumption accessory businesses including e-commerce platforms Grasscity.com and CBDcity.com, and its wholesale distribution division under Valiant Distribution, including the licensed entertainment product manufacturer Famous Brandz. High Tide's strategy as a parent company is to extend and strengthen its integrated value chain, while providing a complete customer experience and maximizing shareholder value.

msa brands

add to watch list Paper trade email alert is off

Vintage Wine Estates Inc

VWE 4 | $0.2649 8.12% 7.51% 180K

|

(0.0% 1d) (-30.7% 1m) (-79.7% 1y) (0.0% 2d) (8.3% 3d) (7.8% 7d) (-18.74% volume)
Earnings Calendar: 2023-11-09
Market Cap: $ 16,625,597
https://www.vintagewineestates.com/
Sec Filling | Patents | 2021 employees

(US) Vintage Wine Estates is a family of wineries and wines whose singular focus is producing the finest quality wines and incredible customer experiences with wineries throughout Napa, Sonoma, California’s Central Coast, Oregon and Washington State. Since its founding 20 years ago, the Company has become a top 15 U.S. wine producer via organic and acquisitive growth, today selling more than 2 million nine-liter equivalent cases annually. To achieve this growth, the Company curates, creates, stewards and markets its many brands and services to customers and end consumers via a balanced omni-channel strategy encompassing direct-to-consumer, wholesale and exclusive brands arrangements with national retailers. VWE is diverse across price points and varietals with over 50 brands ranging from $10-$150 USD at retail, with the majority selling in the $12-$20 USD price range.

brands acquisitions

add to watch list Paper trade email alert is off

CareMax Inc - Class A

CMAX | $2.52 5.0% 4.76% 53K

|

(0.0% 1d) (-59.0% 1m) (17.9% 1y) (0.0% 2d) (0.0% 3d) (-20.9% 7d) (69.14% volume)
Earnings Calendar: 2024-03-07
Market Cap: $ 9,583,265
https://www.caremax.com
Sec Filling | Patents | 962 employees

CareMax is a technology-enabled care platform providing value-based care and chronic disease management to seniors. CareMax operates medical centers that offer a comprehensive suite of healthcare and social services, and a proprietary software and services platform that provides data, analytics, and rules-based decision tools/workflows for physicians across the United States.

add to watch list Paper trade email alert is off

LifeStance Health Group Inc

LFST S | $5.7 -0.18% -0.18% 860K

|

(0.0% 1d) (-6.1% 1m) (-28.9% 1y) (0.0% 2d) (0.4% 3d) (-2.4% 7d) (Infinity% volume)
Earnings Calendar: 2024-02-28
Market Cap: $ 2,169,932,595
https://lifestance.com
Sec Filling | Patents | 4915 employees

(US) Founded in 2017, LifeStance Health is one of the nation's largest providers of virtual and in-person outpatient mental health care for children, adolescents and adults experiencing a variety of mental health conditions. The company delivers personalized, data-driven and comprehensive care to help patients stay healthy and employs over 3,300 psychiatrists, advanced practice nurses, psychologists and therapists. LifeStance Health currently operates across 27 states and over 370 centers.

add to watch list Paper trade email alert is off

Proterra Inc

PTRA | $0.067 -25.56% -34.33% 58M

|

(0.0% 1d) (0.0% 1m) (-94.3% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (21.78% volume)
Earnings Calendar: 2023-11-01
Market Cap: $ 15,262,600
https://www.proterra.com/
Sec Filling | Patents | 709 employees

(US) Proterra, Inc. operates as an automotive and energy storage company. The Company designs and manufactures electric transit buses and electric charging systems. Proterra serves customers worldwide.

energy automotive eletrical

add to watch list Paper trade email alert is off

ATAI Life Sciences N.V.

ATAI | $1.85 -3.14% -3.24% 940K

|

(0.0% 1d) (10.8% 1m) (-14.7% 1y) (0.0% 2d) (-14.2% 3d) (-10.6% 7d) (Infinity% volume)
Earnings Calendar: 2024-03-21
Market Cap: $ 307,148,833
https://www.atai.life
Sec Filling | Patents | 35 employees

(DE) atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London.

treatment profitable msa

add to watch list Paper trade email alert is off

Femasys Inc

FEMY | $1.33 1.53% 1.5% 160K

|

(0.0% 1d) (-23.3% 1m) (47.2% 1y) (3.1% 2d) (1.5% 3d) (-1.5% 7d) (Infinity% volume)
Earnings Calendar: 2022-11-10
Market Cap: $ 29,392,132

Sec Filling | Patents | 35 employees

our experienced management team has over 200 years of collective industry experience with extensive focus in medical devices. the pioneering and collaborative efforts of the management team have created an organization that strives for integrity in all actions, innovation in development activities, excellence in operations, and the highest quality products. the team is complemented by world-class medical advisors. our products have been organically conceived, researched and developed by the company and all manufacturing activities are conducted to ensure compliance with the u.s. food and drug administration (fda) per the requirements of 21 cfr 820, as well as iso 13485. femasys has achieved significant milestones to date, including numerous issued patents and filings, recruitment of a team of experts, clearance of multiple regulatory filings by the u.s. food and drug administration (fda), european union, canada, and japan with other select countries in process. making a difference in t

contraception

add to watch list Paper trade email alert is off

← Previous
1
2
3
4
5
6
7
8
9
…
40
41
Next →

Your Today's Watch List

Sign in to create a watchlist

Gainers vs Losers

67%

33%

Top 10 Gainers

Last 48 Hours Insiders Buying

RXO P 200000 | $19.37 2.32% 0.0% 1M

|

| 23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M

|

| 22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K

|

Health Technology

| 22:30
BCDA P 2750 | $0.377 -1.4% 97K

|

Health Technology

| 22:00
RMCF | $3.67 3.38% 3.27% 11K

|

Consumer Non-Durables

| 20:10

12 months watchlist earnings calendar